Global research trends on Chinese patent drugs inducing programmed cell death in cancer: a bibliometric analysis (1998–2024)
Chinese patent drugs are increasingly recognized as promising agents for modulating PCD in cancer cells. Ongoing work focuses on standardized manufacturing, robust clinical validation, and mechanistic elucidation. These trends position Chinese patent drugs at a pivotal juncture for advancing integrative oncology and enhancing patient outcomes.
Authors
- Min Song
- Che‐Ming Teng (ORCID: https://orcid.org/0000-0002-9719-7334)
- Steven Tan
- Xiaodong Zheng
- Yipeng Guo
Institutions
- Hubei Provincial Hospital of Traditional Chinese Medicine (CN)
- Integrated Chinese Medicine (China) (HK)
- Chongqing Institute of Genetics and Reproduction (CN)
- First People's Hospital of Chongqing (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-06-21
- DOI
- https://doi.org/10.1007/s12672-025-02913-5
- Citations
- 1
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.52